MAP2K7 and cancer: Indeed, the majority of solid tumors are explicitly characterized by their mutations in the RAS/RAF/MEK/ERK genes, wherein highly selective small molecule inhibitors of BRAF and MEK1/2 are currently used for cancer therapy (Figure 1) [4,5,6,7,8].